Press Releases AstraZeneca PLC Xetra

Equities

ZEG

GB0009895292

Market Closed - Xetra Other stock markets 09:05:31 07/06/2024 pm IST			5-day change	1st Jan Change
148.2 ^EUR	0.00%		+3.42%	+21.42%

07/06	ASTRAZENECA : JP Morgan reiterates its Buy rating	ZD
05/06	Department of Health - Abu Dhabi and AstraZeneca Expand Partnership During Bio International Convention 2024 to Establish New Rare Diseases Centre of Excellence	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06	AQ
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'	06/06	AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	06/06	AQ
AstraZeneca - Acquisition of Fusion completed	05/06	AQ
AstraZeneca : Biographies	04/06	PU
AstraZeneca : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K	03/06	PU
AstraZeneca : Transparency Directive - Form 6-K	03/06	PU
AstraZeneca immunotherapy could boost lung cancer survival	03/06	AQ
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K	03/06	PU
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	03/06	BU
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	02/06	PU
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	02/06	BU
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy	02/06	BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	28/05	AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa	28/05	AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension	28/05	AQ
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	27/05	BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	23/05	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	22/05	BU
Astrazeneca looks to double revenue in 'new era of growth'	22/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST